Lumos Pharma, Inc. (LUMO)
USD 4.34
(0.0%)
USD 4.34
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.09 Million | -26.62 Million | -29.64 Million | -22.99 Million | -30.2 Million | -37.93 Million |
| Net Income | -34.03 Million | -31.06 Million | -30.43 Million | -5.66 Million | -42.98 Million | -53.59 Million |
| Depreciation & Amortization | 44 Thousand | 49 Thousand | 203 Thousand | 584 Thousand | 1.09 Million | 1.14 Million |
| Deferred income taxes | -273 Thousand | - | - | -9.5 Million | - | - |
| Stock-based compensation | 2.32 Million | 2.32 Million | 2.87 Million | 1.07 Million | 6.72 Million | 17.12 Million |
| Change in working capital | 965 Thousand | 2.09 Million | -2.31 Million | -3.61 Million | 4.59 Million | -2.71 Million |
| Other non-cash items | -119 Thousand | -26 Thousand | 14 Thousand | -5.87 Million | 371 Thousand | 102 Thousand |
| Investing Cash Flow | 10.74 Million | -11.35 Million | 25.97 Million | 116.64 Million | 77 Thousand | 117 Thousand |
| Investments in PPE | - | -21 Thousand | -30 Thousand | -30 Thousand | -2000.00 | -7000.00 |
| Acquisitions | - | - | - | 84.17 Million | - | 124 Thousand |
| Investment purchases | -7.37 Million | -11.33 Million | - | - | - | - |
| Sales/Maturities of investments | 18.12 Million | - | - | - | - | - |
| Other Investing Activities | 10.74 Million | -11.33 Million | 26 Million | 32.5 Million | 79 Thousand | 124 Thousand |
| Financing Cash Flow | -576 Thousand | -821 Thousand | -192 Thousand | 75 Thousand | -59 Thousand | -148 Thousand |
| Debt repayment | - | - | - | -27 Thousand | -61 Thousand | -167 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1.31 Million | -731 Thousand | -114 Thousand | - | -36 Thousand | -275 Thousand |
| Common Stock Issuance | 760 Thousand | -90 Thousand | -78 Thousand | 116.94 Million | 38 Thousand | 294 Thousand |
| Other Financing Activities | -26 Thousand | -90 Thousand | -78 Thousand | -116.84 Million | 38 Thousand | 294 Thousand |
| Accounts receivables | 13 Thousand | -92 Thousand | 136 Thousand | 309 Thousand | - | 10.22 Million |
| Accounts payables | 273 Thousand | 1.69 Million | -1.36 Million | -3.19 Million | 1.97 Million | -13.02 Million |
| Inventory | - | 92 Thousand | -136 Thousand | -309 Thousand | - | - |
| Other working capital | 679 Thousand | 400 Thousand | -950 Thousand | -422 Thousand | 2.61 Million | 10.31 Million |
| Cash at beginning of period | 56 Million | 94.8 Million | 98.67 Million | 4.95 Million | 120.73 Million | 158.7 Million |
| Cash at end of period | 35.07 Million | 56 Million | 94.8 Million | 98.67 Million | 90.54 Million | 120.73 Million |
| Capital Expenditure | - | -21 Thousand | -30 Thousand | -30 Thousand | -2000.00 | -7000.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -20.92 Million | -38.8 Million | -3.87 Million | 93.72 Million | -30.18 Million | -37.97 Million |
| Free Cash Flow | -31.09 Million | -26.64 Million | -29.67 Million | -23.02 Million | -30.2 Million | -37.94 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7.55 Million | -10.44 Million | -9.45 Million | -34.03 Million | -8.3 Million | -8.93 Million |
| Depreciation & Amortization | 2000.00 | 2000.00 | 18 Thousand | 44 Thousand | 8000.00 | 9000.00 |
| Deferred income taxes | - | - | 159 Thousand | -273 Thousand | - | - |
| Stock-based compensation | 387 Thousand | 580 Thousand | 524 Thousand | 2.32 Million | 559 Thousand | 653 Thousand |
| Change in working capital | 782 Thousand | -3.03 Million | 1.55 Million | 965 Thousand | 4000.00 | 1.71 Million |
| Other non-cash items | -131 Thousand | 3.18 Million | -189 Thousand | -119 Thousand | -91 Thousand | -135 Thousand |
| Investing Cash Flow | - | 1 Million | 6.17 Million | 10.74 Million | 5.95 Million | 1.08 Million |
| Investments in PPE | - | - | -13.2 Million | - | 6.38 Million | -3.91 Million |
| Acquisitions | - | - | 7.03 Million | - | -5.95 Million | -1.08 Million |
| Investment purchases | - | - | -998 Thousand | -7.37 Million | -6.38 Million | -3.91 Million |
| Sales/Maturities of investments | - | 1 Million | 7.17 Million | 18.12 Million | 5.95 Million | 5 Million |
| Other Investing Activities | - | 1 Million | 6.17 Million | 10.74 Million | 5.95 Million | 3.91 Million |
| Financing Cash Flow | - | -5000.00 | 742 Thousand | -576 Thousand | -435 Thousand | -574 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -11 Thousand | -5000.00 | - | -1.31 Million | -426 Thousand | -579 Thousand |
| Common Stock Issuance | 11 Thousand | - | 742 Thousand | 760 Thousand | - | 18 Thousand |
| Other Financing Activities | -11 Thousand | -5000.00 | 742 Thousand | -26 Thousand | -9000.00 | -13 Thousand |
| Accounts receivables | 13 Thousand | 29 Thousand | -38 Thousand | 13 Thousand | 61 Thousand | -32 Thousand |
| Accounts payables | 509 Thousand | -2.62 Million | 757 Thousand | 273 Thousand | -377 Thousand | 1.58 Million |
| Inventory | - | - | 2.33 Million | - | - | - |
| Other working capital | 260 Thousand | -437 Thousand | -1.49 Million | 679 Thousand | 320 Thousand | 169 Thousand |
| Cash at beginning of period | 23.17 Million | 35.07 Million | 35.55 Million | 56 Million | 37.86 Million | 44.03 Million |
| Cash at end of period | 16.79 Million | 23.17 Million | 35.07 Million | 35.07 Million | 35.55 Million | 37.86 Million |
| Capital Expenditure | - | - | -13.2 Million | - | 6.38 Million | -3.91 Million |
| Effect of forex changes on cash | - | - | 8.75 Million | - | -5.99 Million | -2.75 Million |
| Net cash flow / Change in cash | -6.38 Million | -11.89 Million | -479 Thousand | -20.92 Million | -2.3 Million | -6.17 Million |
| Free Cash Flow | -6.38 Million | -12.89 Million | -20.59 Million | -31.09 Million | -1.44 Million | -10.6 Million |
000027
CEYE
600666
SHARPINV
GRA
036710